In Brief: Cortecs/Osteometer BioTech agreement
This article was originally published in The Gray Sheet
Executive Summary
Cortecs/Osteometer BioTech agreement: U.K.-based oral drug delivery firm Cortecs inks a development deal with Danish diagnostics firm Osteometer BioTech A/S to develop a whole blood, point-of-care diagnostic product for the detection of collagen breakdown, an indicator of osteoporosis. Cortecs, calling the deal a "profit-sharing agreement," says that the development effort will combine its rapid diagnostic technologies with Osteometer's Cross-laps bone resorption marker technology. The companies will jointly develop the product, with clinical testing coordinated by The Center for Clinical and Basic Research in Denmark. Cortecs will manufacture the finished product, retain distribution rights for the U.K. and Australia and select distributors for other markets "from international corporations involved in the management of osteoporosis"...
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.